A method for treating tumor by using recombinant interferon with changed spatial configuration

Abstract

The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and/or preventing postoperative tumor recurrence and/or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and/or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

1 - 481 . (canceled) 
     
     
         482 . A method for eliminating or reducing the malignant pleural effusion, malignant ascites, and/or malignant pericardial effusion in a subject with tumor, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2. 
     
     
         483 . The method of  claim 482 , wherein the tumor is a solid tumor. 
     
     
         484 . The method of  claim 482 , wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises one or more of: infiltration administration, intrapleural administration, abdominal administration, pericardial administration, thoracic administration and intraperitoneal administration. 
     
     
         485 . The method of  claim 482 , wherein the recombinant interferon is administered in an amount in a range of about 30 μg to about 2000 μg by one administration. 
     
     
         486 . The method of  claim 484 , wherein the recombinant interferon is additionally administered to the subject by systemic administration. 
     
     
         487 . The method of  claim 482 , wherein the subject is administered with at least one other anti-cancer drug. 
     
     
         488 . The method of  claim 487 , wherein said other anti-cancer drug is selected from the group consisting of chemotherapeutic drug, targeted drug, and biological drug. 
     
     
         489 . A method for preventing tumor recurrence or metastasis, or prolonging or maintaining a tumor-free status in a subject with a tumor, comprising administering to said subject a recombinant interferon encoded by the nucleotide sequence SEQ ID NO: 2, wherein said subject has been treated with at least one anti-cancer therapy before the administration of said recombinant interferon. 
     
     
         490 . The method of  claim 489 , wherein said anti-cancer therapy is selected from the group consisting of chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy. 
     
     
         491 . The method of  claim 489 , wherein said recombinant interferon is administered to said subject in a single dose of the range of about 2 μg to about 2000 μg. 
     
     
         492 . A method for eliminating or reducing metastatic tumor lesion in a subject, comprising administering a recombinant interferon encoded by SEQ ID NO: 2 topically or locally to the tumor lesion. 
     
     
         493 . The method of  claim 492 , wherein the metastatic tumor lesion comprises at least one of: a bone lesion, a muscular lesion, a subcutaneous tissue lesion, a prostatic lesion, and a lymph node lesion. 
     
     
         494 . The method of  claim 492 , wherein the recombinant interferon is administered to the lesion by an administration route, the administration route comprises at least one of: infiltration administration, percutaneous administration, transdermal administration, epidermal administration and transmucosal administration. 
     
     
         495 . The method of  claim 492 , wherein the recombinant interferon is administered topically. 
     
     
         496 . The method of  claim 494 , wherein the recombinant interferon is further administered systemically. 
     
     
         497 . A non-surgical method for eliminating a tumor in a subject or reducing the size of a tumor in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2. 
     
     
         498 . The method of  claim 497 , wherein the tumor is a non-resectable tumor. 
     
     
         499 . The method of  claim 497 , wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, local administration, and topical administration. 
     
     
         500 . The method of  claim 499 , wherein the local administration or topical administration comprises one or more of: intratumoral administration and spray administration. 
     
     
         501 . The method of  claim 497 , wherein the subject is administered at least one other anti-cancer therapy. 
     
     
         502 . The method of  claim 501 , wherein said anti-cancer therapy is selected from the group consisting of chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy. 
     
     
         503 . A method for treating lung cancer in a subject, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, topical administration, and local administration. 
     
     
         504 . The method of  claim 503 , wherein the recombinant interferon is administered systemically and via inhalation. 
     
     
         505 . The method of  claim 504 , wherein the systemic administration comprises at least one of: subcutaneous administration and intramuscular administration, and inhalation comprises at least one of: pulmonary inhalation and nasal inhalation. 
     
     
         506 . The method of  claim 503 , wherein the recombinant interferon is administered locally by perfusion. 
     
     
         507 . The method of  claim 503 , wherein the at least one other anti-cancer therapy is administered to the subject before, simultaneously, and/or after administration of the recombinant interferon.